Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Short-term Investments (2016 - 2025)

Voyager Therapeutics' Short-term Investments history spans 11 years, with the latest figure at $131.1 million for Q4 2025.

  • For Q4 2025, Short-term Investments fell 32.85% year-over-year to $131.1 million; the TTM value through Dec 2025 reached $131.1 million, down 32.85%, while the annual FY2025 figure was $131.1 million, 32.85% down from the prior year.
  • Short-term Investments for Q4 2025 was $131.1 million at Voyager Therapeutics, down from $163.8 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $294.9 million in Q2 2024 and bottomed at $5.0 million in Q1 2023.
  • The 5-year median for Short-term Investments is $100.4 million (2022), against an average of $112.2 million.
  • The largest annual shift saw Short-term Investments plummeted 85.72% in 2023 before it skyrocketed 5036.99% in 2024.
  • A 5-year view of Short-term Investments shows it stood at $15.1 million in 2021, then skyrocketed by 31.66% to $19.9 million in 2022, then skyrocketed by 714.89% to $162.1 million in 2023, then rose by 20.51% to $195.3 million in 2024, then plummeted by 32.85% to $131.1 million in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Short-term Investments are $131.1 million (Q4 2025), $163.8 million (Q3 2025), and $171.7 million (Q2 2025).